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Introduction: The question whether universal growth charts can be used in multi-ethnic 
settings is of general interest. The Intergrowth-21st (IG-21) fetal growth and newborn size 
standards are suggested to represent optimal fetal growth regardless of country origin. Our 
aim was to examine whether women fulfilling the strict IG-21 inclusion criteria were 
healthier, showed less ethnic differences in fetal growth and newborn size, and  less adverse 
perinatal outcomes. Material and methods: Data were drawn from a population-based multi-
ethnic cohort of 823 presumably healthy pregnant women in Oslo, Norway. We assessed 
differences in fetal and neonatal gestational age specific z-scores and compared maternal 
health parameters, pregnancy- and birth complications between pregnancies fulfilling and not 
fulfilling the IG-21 criteria. Results: Only 21% of pregnancies enrolled in our cohort fulfilled 
the IG-21 criteria. Fetal growth deviated substantially from the new standards, in particular 
for ethnic Europeans. Ethnic differences persisted in pregnancies fulfilling the criteria.In 
South Asian fetuses estimated fetal weight was -0.60 SD (95% CI: -1.00, -0.20) lower at 24 
gestational weeks, and birthweight was -0.62 SD (-0.95, -0.29) lower, compared with ethnic 
Europeans. Corresponding numbers for Middle-East/N-Africans were -0.13 (-0.62, 0.36) and -
0.60 (-1.00, -0.20). Maternal health indicators and birth complications were similar in women 
fulfilling and not fulfilling the criteria, or the relation depended on ethnic origin. Conclusions: 
In an urban multi-ethnic Norwegian population, applying an extensive list of criteria to define 
“healthy“ pregnancies excludes the majority of women but does not cancel ethnic differences 
in fetal growth. 
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Abbreviations 
AC  abdominal circumference 
CH-length crown-heel length 
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EFW  estimated fetal weight 
FL  femur length 
HC  head circumference 
IG-21  Intergrowth-21st fetal growth and newborn size standards 
 
Key message 
Is one growth standard universally applicable, as concluded by the Intergrowth-21st 
consortium, or are modifications needed to fit various populations or ethnicities? In our multi-
ethnic population, strict inclusion criteria, as in Intergrowth-21st, did not uniformly identify 
women with better health or less adverse perinatal outcomes, and ethnic differences in fetal 






Growth charts are important clinical tools, and can be constructed as “growth references” or 
“growth standards”. A growth reference simply describes the growth in a given population. A 
growth standard, on the other hand, is based on the assumption that fetuses regardless of 
ethnic background grow similarly under optimal health, environmental and socioeconomic 
conditions.  In 2014, new international fetal growth and newborn size standards suggested for 
universal use were introduced by the Intergrowth-21st (IG-21) consortium, based on samples 
of pregnant women from all world regions fulfilling strict inclusion criteria (1, 2). The IG-21 
consortium concluded that the sample represented healthy pregnant women where nutritional 
and health needs were met, and hence that the derived growth charts would represent “optimal 
growth”, regardless of ethnic origin (3, 4). However, two recent studies also aiming at 
producing fetal growth charts for general use, dispute the IG-21 conclusions (5, 6).  
In multi-ethnic populations, it is essential to know whether one single growth chart can be 
used for all, as concluded from the IG-21 study, or if population-specific reference ranges are 
more appropriate. To address this question, we used the multi-ethnic population-based 
STORK-Groruddalen cohort in Oslo, Norway, which have detailed information on a wide 
range of maternal health parameters, almost all factors included in the IG-21 criteria, and fetal 
growth and newborn size. The aim of the present study was to test the validity of the IG-21 
conclusions. If valid we could expect that: 1) applying such criteria would cancel ethnic 
differences in fetal growth and newborn size, and growth measures would align with the IG-
21 sample mean at each time point. 2) women, across ethnic groups, fulfilling the strict IG-21-
criteria would be generally healthier and have less adverse perinatal outcomes in comparison 
to those who do not. 
 
Material and methods 
Study sample  
In Norway, women with low-risk pregnancies are provided antenatal care in primary health 
care, free of charge. Most women attend and rates for adverse perinatal outcomes are 
generally low, although some ethnic differences exist (7, 8). Groruddalen, Oslo, has a multi-
ethnic population with a diverse socio-economic status, and the majority of pregnant women 
(75-85%) attend local Maternal and Child Health Clinics for antenatal care.  
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Stork Groruddalen is a population-based cohort study of pregnant women recruited during 
early pregnancy at three local Maternal and Child Health Clinics from May 2008 to May 2010 
(9). Questionnaire data was collected by specially trained midwifes through interviews, 
supported by a professional interpreter using a translated questionnaires when needed. The 
women were eligible if they 1) were living in one of the three city districts, 2) would give 
birth at one of the two study hospitals, 3) were at less than 20 gestational weeks, 4) were not 
suffering from diseases necessitating intensive hospital follow-up during pregnancy 
(including pre-gestational diabetes), 5) could speak Norwegian or one of eight other 
languages, and 6) were able to provide informed written consent. Overall participation rate 
was 74% (ranging between 63 and 82% between ethnic groups) and the study cohort was 
found representative for women attending the Maternal and Child Health Clinics with respect 
to ethnicity and age (9).  
 
Maternal variables 
Factors included in the Intergrowth-21st study inclusion criteria 
The two IG-21 study samples; Newborn Cross-Sectional Study Prescriptive Subpopulation 
and the Fetal Growth Longitudinal Study, used the same inclusion criteria, hereafter referred 
to as the “IG-21 criteria” (Table 1). Data was collected at eight study sites, representing all 
world regions (3). Large study samples were first selected at a population level, by recruiting 
from hospitals serving populations with middle- and high socio-economic status. Secondly, 
women were selected at an individual level, based on a number of clinical and nutritional 
indicators associated with intra-uterine growth restriction (Table 1)(3, 4). In the Stork-
Groruddalen cohort we had information on all except four IG-21-criteria (“previous 
pregnancy affected by pre-eclampsia/eclampsia, HELLP syndrome or a related pregnancy-
associated condition”, “positive urine-analysis”, “clinically significant atypical red cell 
alloantibodies” and “in an occupation with risk of exposure to chemicals or toxic substances, 
or very physically demanding activity” ) (9). The numbers for these four outcomes were 
presumably low in our population. Furthermore, occupational exposures/activity in relation to 
pregnancy is strictly regulated by law in Norway. Hence, the last of these criteria will not 
apply in this setting.  As some IG-21-criteria cut-off values were site-specific (e.g. 




Other maternal variables 
Maternal and offspring ethnic origin was defined by the pregnant participant’s country of 
birth. If the participant’s mother was born outside Europe or North-America, the country of 
origin was defined by the participant’s mother’s country of birth. Except for Pakistanis (30% 
second generation immigrants), very few women of non-European origin were born in 
Norway. Women were merged into five groups (see footnote Table 1); Europe (n=379), South 
Asia (n=200), East Asia (n=43), Middle-East/North-Africa (n=172) and Others (n=29).  
Pre-pregnant body mass index (kg/m2) was calculated using self-reported pre-pregnant weight 
and measured height (9). Maternal skin folds were measured twice (triceps, subscapular and 
suprailiac, with Holtain T/W Caliper 0-48mm (Holtain Ltd., Crymych; UK), and the mean of 
the sum was used (11). Weight gain from pre-pregnancy to 28 gestational weeks was 
calculated from measured weight at 28 gestational weeks and the self-reported pre-pregnant 
weight. Weight gain from gestational 28 gestational weeks to birth was calculated from total 
weight gain, self-reported at the post-natal visit, and weight at 28 gestational weeks. Parity 
was categorized as para 0, para 1 or multipara, provided pregnancies lasted at least 22 
gestational weeks. Self-reported regular physical activity at inclusion was classified as 
“regular physical activity” or “no regular physical activity” according to specific criteria (see 
footnote Table 2) (9). 
Fasting venous blood samples were drawn at inclusion and analysed at certified laboratories 
(9). Severe vitamin D deficiency was defined as 25(OH) vitamin D below 25 nmol/L. A 
standard 75 g oral glucose tolerance test was performed at 28±2 gestational weeks. 
Gestational diabetes mellitus was diagnosed according to the1999 World Health Organization 
criteria (fasting plasma glucose ≥7 mmol/l or 2-hour plasma glucose ≥7.8 mmol/l) (9, 12). 
 
Pregnancy and birth complications 
Data on birth complications and hypertensive disorders in pregnancy (systolic blood 
pressure >140 mmHg and/or diastolic blood pressure >90 mmHg in early pregnancy, or after 
20 gestational weeks, accompanied by new-onset proteinuria) were retrieved from hospital 
records. A composite birth complication variable was constructed based on the presence of at 
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least one of three events (acute cesarean section, grade 3-4 perineal rupture and Apgar score < 
7 at 5 min). 
 
Offspring variables 
Gestational age was derived from the first day of the woman’s last menstrual period, unless 
this differed more than 14 days from that derived from the routine ultrasound measurements 
at 17-20 gestational weeks (<7% of women); then the latter was preferred. This differs 
slightly from the Intergrowth-21st study, where gestational age based on an early ultrasound 
scan (at 9-13 gestational weeks) was used if the last menstrual period dating differed more 
than seven days (2). Preterm birth was defined as birth before 37+0 gestational weeks.  
  
Fetal ultrasound measurements 
We measured head circumference (HC), abdominal circumference (AC), and femur length 
(FL) (13) and the mean of three measurements was entered in the statistics. Estimated fetal 
weight (EFW) was calculated using Combs formula: EFW=(0.23718 x AC2 x FL) + (0.03312 
x HC3) (14). Four experienced clinicians (two obstetricians and two ultrasound midwives, 
trained at the same hospital) carried out the ultrasound examinations at 24, 32 and 37 
gestational weeks according to a study-specific standardized protocol using Voluson Pro (GE-
Healthcare) with a AB2-7 scan head. At each session, participants were randomly allocated to 
the available ultrasound examiner.  
Interrater sessions were performed on 24 pregnant women. Two examiners participated in 
each session, and they performed in total 8-15 examinations each. The intra-class correlation 
coefficient ranged from 0.95 (FL) to 0.99 (HC, AC and EFW.  
Neonatal measurements 
Birthweight was routinely measured in grams on calibrated electronic scales immediately 
after birth. Within 72 hours after birth, detailed anthropometric measurements were taken, 
according to protocol, by specially trained study midwives on the majority (72%) of term 
neonates (9, 11). Bi-annual interrater sessions were performed. Crown-heel length (CH-





Differences between pregnancies fulfilling and not fulfilling all but four IG-21-criteria 
(hereafter referred to as “pregnancies fulfilling the IG-21 criteria”) in total and stratified by 
ethnic origin (three largest groups only), were tested by t-tests for continuous and chi-square 
tests for categorical variables.  
We derived z-scores for each offspring in the Stork-G cohort, using the z-score calculators 
available at the Intergrowth-21st homepage, based on the IG-21 Fetal Growth Longitudinal 
Study sample (HC, AC and FL from 14-42 gestational weeks) and from the IG-21 Newborn 
Cross-Sectional Study sample (weight, HC and CH-length at birth). As standards for EFW 
during pregnancy and AC at birth are not available from the IG-21 samples, we derived z-
scores using a Norwegian reference population and our own study sample to investigate 
ethnic differences (11, 13).  We then plotted mean z-scores against the IG-21 standard mean 
at each time point, and assessed ethnic differences in mean fetal and neonatal size (mean z-
scores) within our cohort, and, restricting the sample to pregnancies lasting more than 37 
gestational weeks. SPSS version 22.0 for Windows (SPSS Inc., Chicago, IL, USA) was used. 
The significance level set to ≤0.050. 
 
Ethical approval 
The study protocol was approved by The Regional Committee for Medical and Health 




Of 823 women included in the Stork-Groruddalen study only 173 (21%) fulfilled the IG-21 
criteria, ranging from 16 to 25% for different ethnic groups (Table 1).  Approximately 20% in 
all ethnic groups were excluded for reasons related to their last menstrual period date (Table 
1). Other prevalent causes for exclusion were pre-pregnancy smoking, low education, anemia 
(Hemoglobin < 11 g/dl), age >35 years and obesity (body mass index >30 kg/m2), but varied 
by ethnicity. Applying the IG-21-criteria excluded the majority of multiparous Middle 
East/N-African women, while this was not seen in the two other ethnic groups (Table 2). 
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Does applying the IG-21 criteria cancel ethnic differences in fetal growth and newborn size?   
Compared with the IG-21 fetal growth standard, fetuses in the Stork-G cohort had smaller 
HC, longer FL, and larger AC during pregnancy (Figure 1a and Supporting Information Table 
S1). At birth, all three measurements were larger than the IG-21 newborn size standard. 
Restricting the sample to women fulfilling the IG-21-criteria had little impact on the observed 
deviations. Compared with the IG-21 newborn size standard, European newborns in particular 
had larger HC, as 36% of ethnic European neonates had HC above the 90th percentile at birth 
(Table S1 and Supporting Information Figure S1). This increased to 47% in women fulfilling 
the IG-21-criteria (Table S1 and Table S1).  
Compared with ethnic Europeans, South Asian fetuses were slightly smaller, while Middle 
East/N-African fetuses had similar EFW in mid pregnancy (Figure 2). However, fetuses in 
both ethnic minority groups had higher mean FL at this stage of pregnancy (Figure S1 (a)) 
and grew more slowly until birth (Figure 1) for all three body measurements (Figure S1 (a)). 
When restricting the sample to women fulfilling the IG-21 criteria, ethnic differences 
persisted, and for birthweight even increased (Figure 1). The ethnic differences in FL at mid-
pregnancy, however, decreased (Figure S1 (d)). 
Do the IG-21-criteria identify pregnant women with better health and fewer adverse perinatal 
outcomes? 
Overall, fewer women fulfilling the IG-21 criteria developed gestational diabetes, compared 
with those not fulfilling the criteria (Table 2). However, this difference was significant only in 
South Asians, while no such trend was observed in Europeans (Table 3 and 4). Women 
fulfilling the criteria were slightly less adipose, and had slightly lower serum triglyceride 
levels in early pregnancy (Table 2). However, this difference was not observed in South 
Asians (Table 3). Women fulfilling the criteria gained more weight during pregnancy (Table 2 
and 3). 
More ethnic minority women had severe vitamin D deficiency, depressive symptoms and 
were physically inactive than ethnic European women (Table 3), with no significant 
difference between women fulfilling or not fulfilling the IG-21 criteria. Thus, these ethnic 
differences persisted. 
The caesarean section rate was less than half of that in the IG-21 study (Table 2)(4). Overall, 
we did not observe significant differences between women fulfilling or not fulfilling the 
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criteria for adverse birth outcomes, such as acute caesarean section, grade 3-4 perineal tear or 
low Apgar-score (Table 2 and 4).  
 
Discussion 
In this multi-ethnic cohort of presumably healthy pregnant women with expected low-risk 
pregnancies in Norway, only 21% fulfilled  the inclusion criteria used for the IG-21 standards. 
Fetal growth and newborn size deviated notably from the IG-21 standards, in particular for 
ethnic Europeans. The fact that those selected according to such strict criteria still maintained 
ethnic differences in fetal growth and newborn size, challenges the concept that one growth 
standard fits all. Further, the criteria excluded women differently in various ethnic groups, and 
those fulfilling the IG-21 criteria were not consistently “healthier” or had fewer adverse 
perinatal outcomes, and importantly, the relations varied by ethnicity.  
Several studies have demonstrated that some maternal factors, such as anthropometric 
parameters and current socioeconomic level, affect fetal growth and perinatal outcomes 
differently according to ethnic groups and settings, possibly due to different stages of 
sociodemographic transition (15-18). Additionally, a range of other maternal factors also 
influence fetal growth (19-22) interacting with each other, and with genetic factors, as part of 
the adaptive responses made by the fetus to tune its development appropriately to the current 
conditions (23). Hence, the nature of these relations, and whether they are similar across 
different populations, ethnicities and cultures, are scantily understood and therefore possibly 
not well represented in current inclusion and exclusion criteria.  
This is in line with our findings that women fulfilling the IG-21 criteria may not necessarily 
be optimally nourished. I.e. more than half of South Asian women fulfilling the criteria had 
severe vitamin D deficiency, while this was rare in Europeans. Although the independent 
effect of vitamin D in the regulation of fetal growth has not been established, there are data 
supporting that maternal vitamin D status may influence obstetric outcomes and fetal tissue 
development (24). In contrast, South Asian women fulfilling the IG-21 criteria had less while 
European women had similar prevalence of gestational diabetes as women not fulfilling the 
criteria. This could indicate that the IG-21 criteria do not identify risk of gestational diabetes 
similarly in all ethnic groups and hence that the IG-21 growth standards may not reflects 
“optimal conditions for fetal growth” in all settings. 
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In our multi-ethnic cohort, we found ethnic differences in fetal and neonatal size irrespective 
of whether IG-21 criteria were fulfilled. This is in accordance with findings from the two 
recent studies aiming to develop new fetal growth charts; one from USA including women 
from four ethnic groups (White, Hispanic, Black and Asian) (5), and another from the World 
Health Organization including 10 countries worldwide (6). In both studies, differences based 
on ethnic origin or country were observed from early pregnancy, and were only partially 
explained by known maternal factors.  
Customizing growth charts according to maternal factors including ethnicity has long been a 
promising method of refining the diagnostic application (25). The recent insights imply that 
such customization may need a more differential approach than a crude shift in mean and 
standard deviation to fit individual diagnostic needs (6). E.g. intrauterine growth may follow 
different trajectories according to population background and size of fetus (5). 
In addition to not being an appropriate standard for expected healthy fetal growth for all, it is 
a concern that the use of a universal standard in clinical practice could lead to over-diagnosing 
both large and small for gestational age fetuses. Ethnic Norwegian newborns are among the 
largest in the world, with a mean birthweight of almost 3700 g at full term (26). E.g. almost 
half of ethnic European neonates in our cohort had HC >90 percentile. In other populations, 
specifically in Asia, where mean birth weight is lower, the opposite would be the case, as 
demonstrated in a Chinese population (27). This could have far-reaching consequences for 
clinical care. Furthermore, if the criteria aiming to identify women that offer “optimal 
conditions for fetal growth” do not identify women with better perinatal outcomes, one might 
question if adopting such standards could do more harm than good, at least for some ethnic 
groups. 
Our study has several strengths, including the population-based design and a multi-ethnic 
setting. We had information on almost all variables used in the IG-21-study, including 
maternal data from early pregnancy and offspring growth data from mid gestation until birth, 
and a wide range of other variables on maternal clinical parameters and obstetric outcomes. 
However, our study has some limitations. Applying the criteria on our cohort reduced the 
number of participants substantially and thereby the statistical power. This limited our 
possibility to address differences in rare, but perhaps more specific perinatal outcomes, such 
as perinatal mortality.  
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Fetal FL was substantially longer in our cohort, compared with the mean from the IG-21-
standard. This is in accordance with recent studies from France and Greece (28, 29). 
Furthermore, in our cohort HC was smaller during pregnancy, but larger at birth, compared 
the IG-21. Whether this discrepancy reflects a systematic difference in measurements 
performed before or after birth between the studies, is unknown. Anthropometric 
measurements are known to be sensitive to inter-observer variation. Although all our 
biometric data were measured according to a strict protocol, comparable to the one used in the 
Intergrowth-21st studies, such bias cannot be ruled out. However, this would not explain the 
observed ethnic differences within our cohort.  
We are just starting to understand the complexity of fetal growth regulation governed by 
genetic as well as numerous environmental factors. Our study shows that when using very 
strict maternal factors to define “healthy” pregnancies, we end up with very few pregnancies. 
Even under such “optimal” conditions we do not observe less deviation from the growth 
standards, reduced ethnic differences in fetal growth or newborn size, consistently better 
maternal health or fewer adverse perinatal outcomes. Hence, we question the validity of using 
a universal standard. 
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Supporting Information legends 
 
Figure S1. Ethnic differences in fetal head circumference (HC), length, (measured as femur length 
(FL) during pregnancy and crown-heel length at birth) and abdominal circumference (AC) in ethnic 
South Asians (left panel) and Middle East/N-Africans (right panel), compared with ethnic Europeans 
(zero-line in both figures). Figure a and c present differences in total Stork-Groruddalen cohort and b 
and d in those fulfilling the Intergrowth-21st inclusion criteria. Results are presented as differences in 
mean z-score (95% CI). Numbers includes only live born, singleton neonates, with valid birth data and 
at least one ultrasound measurement, born at more than 37 gestational weeks (179 South Asian, 158 
Middle East/N-African and 346 ethnic European in the total cohort and 44, 25 and 78, respectively, in 
pregnancies not fulfilling the IG-21 criteria). 
 
Table S1. Mean fetal and neonatal z-scores, and the proportion classified large or small for gestational 







Figure 1. Mean z-scores of fetal/neonatal measures in the Stork Groruddalen cohort at 24, 32 and 37 
weeks’ gestation and at birth, according to the new Intergrowth-21st fetal growth and newborn size 
standards); (a) in the total cohort and (b) in pregnancies fulfilling the Intergrowth-21st (IG-21) 
inclusion criteria. Measures are mean z-scores (95% CI) of head circumference (HC, circles), length 
(measured as femur length (FL) in pregnancy and crown-heel length at birth, squares), abdominal 
circumference (AC, white triangles) and birth weight (black triangles). . The zero-line represents the 
mean in the Intergrowth-cohorts. Numbers include only live born, singleton neonates with valid birth 
data and at least one ultrasound measurement (164 pregnancies fulfilling, and 608 pregnancies not 





Figure 2. Ethnic differences in estimated fetal weight (EFW) and birth weight, in ethnic South Asians 
(white circles) and Middle East/N-Africans (black squares), compared with ethnic Europeans (zero-
line) in the Stork-Groruddalen cohort; (a) in the total cohort and (b) in pregnancies fulfilling the 
Intergrowth-21st (IG-21) inclusion criteria. Results are presented as differences in mean z-score (95% 
CI). Numbers includes only live born, singleton neonates, with valid birth data and at least one 
ultrasound measurement, born at more than 37 gestational weeks (179 South Asian, 158 Middle 
East/N-African and 346 ethnic European in the total cohort and 44, 25 and 78 respectively in 






Table 1. Proportion of women in the Stork-Groruddalen cohort (n (%)) excluded if applying 











    n=823 n=379 n=200 n=43 n=172 n=29 
Demographics/anthropometrics             
  Age <18 yearsf 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
  Age ≥35 years 127 (15) 66 (17) 18 (9) 11 (26) 28 (16) 4 (14) 
  Height<153 cm 41 (5) 3 (0.8) 16 (8.0) 10 (23) 8 (5) 4 (14) 
  Pre-pregnant BMI <18.5 kg/m2 54 (7) 20 (5) 20 (10) 4 (9) 9 (5) 1 (3) 
  Pre-pregnant BMI ≥30 kg/m2 113 (14) 47 (12) 19 (10) 2 (5) 37 (22) 8 (28) 
  Low education (primary or less) 133 (16) 15 (4) 35 (18) 8 (19) 72 (42) 3 (10) 
Last menstrual period dating issues             
  Any uncertainty related to LMP datingg 175 (21) 78 (21) 44 (22) 13 (30) 26 (21) 4 (14) 
  No recall of LMP date 27 (3) 18 (5) 3 (2) 0 (0) 6 (4) 0 (0) 
  Hormonal contraceptive use last 2 cycles 74 (9) 47 (12) 12 (6) 2 (5) 12 (7) 1 (3) 
  IVF/hormonal induction 13 (2) 10 (3) 1 (0.5) 0 (0) 2 (1) 0 (0) 
Obstetric issues/history             
 Twin pregnancy 11 (1) 4 (1) 2 (1) 1 (2) 3 (2) 1 (3) 
  Two or more previous miscarriages 52 (6) 24 (6) 15 (8) 3 (7) 7 (4) 3 (10) 
  Previous preterm delivery 22 (3) 5 (1) 13 (7) 0 (0) 4 (2) 0 (0) 
  Previous birthweight <2500 g 31 (4) 4 (1) 13 (7) 1 (2) 12 (7) 1 (3) 
  Previous birthweight >4500 g 11 (1) 3 (0.8) 0 (0) 0 (0) 8 (5) 0 (0) 
  Previous stillbirth/perinatal death 8 (1) 2 (0.5) 3 (2) 0 (0) 2 (1) 1 (3) 
  Previous preeclampsia -  - -  -  -  -  
Medical issues at inclusion             
  Medical history/medicationh 59 (7) 26 (7) 18 (9) 1 (2) 14 (8) 0 (0) 
  Any smoking last 3 mo prior to pregnancy 143 (18) 117 (31) 4 (2) 4 (9) 16 (9) 2 (7) 
  Heavy alcohol use in pregnancy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
  Positive urine-analysis No info  - -  -  -  -  
  Systolic blood pressure>140 mmHg 2 (0.2) 2 (0.5) 0 (0) 0 (0) 0 (0) 0 (0) 
  Diastolic blood pressure>90 mmHg 4 (0.5) 4 (1) 0 (0) 0 (0) 0 (0) 0 (0) 
  Anemia (Hb<11 g/dl) 112 (14) 30 (8) 37 (19) 7 (16) 33 (19) 5 (17) 
  Treatment for anemia 46 (6) 13 (3) 18 (9) 4 (9) 11 (6) 0 (0) 
  Sexually transmitted disease (Lues, HIV) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
  Atypical red cell alloantbodies -  - -  -  -  -  
  High risk occupationi -  - -  -  -  -  
  Total remaining after excl. on any criterion 173 (21) 81 (22) 49 (25) 8 (19) 28 (16) 5 (17) 
 
a Europe (mainly Scandinavia). 
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b South Asia (Pakistan, Sri Lanka, India). 
c East Asia (mainly Vietnam, the Philippines and Thailand). 
d Middle-East/North-Africa (mainly Iraq, Turkey, Morocco, Somalia) and  
e Others (other Sub-Sahara African and S/C-American countries). 
 f Not specified exclusion criteria in Stork-Groruddalen study, but one woman was excluded partly for this 
reason, social considerations. 
gMay be related to somewhat irregular cycles, contraceptive use last cycles, IVF-pregnancy, bleedings in early 
pregnancy, uncertain recall of exact date etc. 
h Conditions during the last three months before pregnancy/during pregnancy with need of regular medication or 
treatment. Isolated pollen-allergy, eczema and hyperemesis were not excluded.  The most common conditions 
were asthma, hypothyroidism, psychiatric disorders (mainly depression), urinary tract infections, hypertension 
and hormonal medication related to fertilization treatment. 
i In an occupation with risk of exposure to chemicals or toxic substances, or very physically demanding activity. 
Such occupational activity during pregnancy is regulated by law in Norway. 











Table 2. Maternal characteristics and pregnancy and birth complications in women 
participating in the Stork-Groruddalen cohort (left panel), either fulfilling or not fulfilling all 
Intergrowth-21st (IG-21) inclusion criteria. The right panel represents comparable numbers 
from the two Intergrowth-21st study samples; the Fetal Growth Longitudinal Study (FGLS) 
and the Newborn Cross-Sectional Study Prescriptive Subpopulation (NCSS-PS).  
     Stork-G   Intergrowth-21st 















Maternal characteristics        
Incl. in Intergrowth-21st criteria           
 Maternal age (years) 29.4 (3.6) 30.0 (5.2) 0.02 28.4 (3.9) 28.0 (4.0) 
 Years of formal education (years) 14.5 (2.4) 12.7 (3.7) <0.001 15.0 (2.8) 14.2 (3.0) 
 Height (cm) 164.5 (6.1) 163.4 (6.8) 0.06 162.2 (5.8) 161.8 (5.6) 
 Pre-pregnant BMI (kg/m2) 23.3 (2.6) 25.0 (5.2) <0.001 23.3 (3.0) 23.4 (2.9) 
 Hemoglobin level (g/dl) 12.3 (0.7) 12.0 (1.0) <0.001 12.5 (1.1) 12.3 (1.2) 
Not incl. in Intergrowth-21st criteria      
 Parity     0.03     
   Para 0 92 (53) 289 (45)   2955 (68%) 12996 (63%) 
   Para 1 59 (34) 221 (34)   ÷ ÷ 
   Multipara 22 (13) 140 (22)   ÷ ÷ 
 Married or cohabiting 169 (98%) 607 (93%) 0.03 4204 (97%) 19877 (97%) 
 Weight (kg) 64.6 (9.2) 68.8 (15.3) <0.001 61.3 (9.1) 61.3 (8.6) 
 Sum of skinfolds (mm) 68.4 (16.7) 73.3 (20.6) 0.005 ÷ ÷ 
 Triglycerides (mmol/l) 1.20 (0.41) 1.35 (0.58) 0.002 ÷ ÷ 
 Fasting glucose (mmol/l) 4.41 (0.43) 4.43 (0.42) 0.6 ÷ ÷ 
 Severe vitamin D-deficiencya 36 (21) 142 (22) 0.8 ÷ ÷ 
 Depressive sympt. (EPDS-score>10)b 18 (12) 78 (13) 0.6 ÷ ÷ 
 No regular physical activityc 125 (72%) 490 (75%) 0.5 ÷ ÷ 
 1. -2. trimester weight gain (kg) 9.0 (4.3) 8.5 (4.8) 0.3 ÷ ÷ 
 3.trimester weight gain (kg) 6.0 (3.8) 5.1 (4.1) 0.02 ÷ ÷ 
Pregnancy complications      
 Gestational diabetes mellitusd 13 (8%) 86 (14%) 0.03 ÷ ÷ 
 Hypertensive disorder in pregnancye 9 (5%) 37 (6%) 0.8 ÷ ÷ 
 Preeclampsiae 3 (2%) 8 (1%) — 31 (<1%) 256 (1%) 
Birth outcomes      
 Spontaneous initiation of labourf 136 (81%) 468 (74%) 0.1 2868 (66%) 13470 (66%) 
 Cesarean sectionf 26 (15%) 112 (17%) 0.5 1541 (36%) 7452 (36%) 
 Preterm birth (<37 gestational weeks)f 9 (6%) 44 (7%) 0.5 195 (5%) 1136 (6%) 
 Acute cesarean sectiong 19 (12%) 64 (11%) 0.7 ÷ ÷ 
 Grade 3-4 perineal tearg 4 (3%) 19 (3%) — ÷ ÷ 
 Apgar score < 7 at 5 ming 0 (0%) 8 (1%) — ÷ ÷ 
 Composite three complicationsg, h 23 (16%) 78 (15%) 0.7 ÷ ÷ 
 Gender boyg 73 (46%) 300 (52%) 0.2 2149 (50%) 10482 (51%) 
22 
 
 Gestational age at birth (days)g 282 (9) 281 (9) 0.2 ÷ ÷ 
 Birthweight (g)g 3511 (472) 3470 (505) 0.4 3.3 kg (0.4) 3.3 kg (0.5) 
 Head circumferenceg 35.1 (1.4) 34.8 (1.4) 0.03 33.9 (1.3) 33.9 (1.3) 
 Crown-heel-lengthg 50.1 (2.0) 50.0 (2.1) 0.2 49.4 (1.9) 49.3 (1.8) 
 Low birth weight (<2500 g)g 2 (1%) 13 (2%) — 128 (3) 651 (3%) 
Numbers are n (%) or mean (SD). Differences between women in the Stork-Groruddalen (Stork-G) fulfilling, 
compared women not fulfilling the IG-21 criteria, were assessed using chi-square tests for categorical and t-tests 
for continuous variables. Significant differences (p-values <0.05) are written in bold. All variables, except 
depressive symptoms (28 gestational weeks) and weight gain (28 gestational weeks (missing in 7% of women) 
and post-partum (missing in 24% of women) were assessed at inclusion (mean: 15 gestational weeks). There are 
few (<1-2%) missing values for variables reported at inclusion, most participants have no missing variables.
  
a Maternal 25 OH vit D < 25 nmol/L.  
bMeasured at 28 gestational weeks, by the Edinburgh Postnatal Depression Scale.   
c Regular physical activity defined as either 1) moderately intensive activity for 30 min for ≥5 days/week, 2) 
moderately intensive activity for 2.5 h/week over ≥3 days, 3) vigorous-intensity activity for ≥20 min three times 
per week, or 4) activity of both moderate and vigorous intensity in 1 or 2. 
d Gestational diabetes defined by WHO 1999 criteria; Fasting plasma glucose ≥7 or 2-hour plasma glucose ≥7.8 
mmol/l by oral glucose tolerance screening test at 28 gestational weeks or diagnosed at any time during 
pregnancy. 
e Hypertensive disorder in pregnancy defined as systolic blood pressure > 140 mmHg and/or diastolic blood 
pressure > 90 mmHg occurring after 20 gestational weeks , whether or not accompanied by new-onset 
proteinuria. Numbers presented are from hospital records.  Preeclampsia represents women diagnosed with 
hypertensive disorder from before 34 gestational weeks and/or with important clinical significance, as defined by 
hospital records. Numbers are likely not fully comparable with the numbers from Intergrowth-21st. 
f As in the Intergrowth-21st study, numbers are calculated from live born, singleton neonates with birth data. In 
total there were 13 abortions, 8 stillbirths/perinatal deaths, 11 twin-pairs and 8 were lost to follow-up with no 
birth data. 
gAs in the Intergrowth-21st study numbers are calculated from live born, singleton neonates, born at more than 37 
gestational weeks, with birth data (84% and 82% of the total number of births in the respective group).  
hComposite score of three complication; acute cesarean section, grade 3-4 perineal rupture and Apgar score < 7 
at 5 min. 





















Table 3. Maternal characteristics in women fulfilling, compared with women not fulfilling the Intergrowth-21st criteria (IG-21 criteria), stratified 
by ethnicity.  
     Europe   South Asia   Middle East/N-Africa   
 























 n=83 n=296   n=49 n=151   n=28 n=144   
Characteristics included in IG-21 criteria          
 Maternal age (years) 30.2 (2.9) 30.9 (4.8) 0.2 29.1 (3.9) 28.5 (4.7) 0.5 27.2 (4.1) 29.6 (5.7) 0.03 
 Years of formal education (years) 15.4 (2.3) 14.4 (2.7) 0.004 13.6 (2.3) 12.4 (2.8) 0.008 9.3 (2.0) 13.6 (2.3) <0.001 
 Height (cm) 167.3 (5.8) 167.1 (5.7) 0.9 161.6 (5.1) 159.5 (5.8) 0.03 163.5 (5.3) 161.6 (5.5) 0.1 
 Pre-pregnant BMI (kg/m2) 23.2 (2.6) 24.9 (5.1) 0.004 23.3 (2.7) 23.9 (4.6) 0.4 23.4 (2.7) 26.5 (5.7) 0.005 
 Hemoglobin level (g/dl) 12.4 (0.7) 12.3 (0.9) 0.3 12.2 (0.7) 11.6 (1.0) <0.001 12.1 (0.7) 11.8 (1.0) 0.1 
Characteristics not included in IG-21 criteria          
 Parity     0.3     0.7     0.004 
   Para 0 49 (59%) 155 (52%)   23 (47%) 61 (40%)   15 (54%) 47 (33%)   
   Para 1 29 (35%) 108 (37%)   14 (29%) 51 (34%)   11 (39%) 40 (28%)   
   Multipara 5 (6%) 33 (11%)   12 (25%) 39 (26%)   2 (7%) 57 (40%)   
 Married or cohabiting 83 (100%) 278 (94%) 0.02 48 (98%) 149 (99%) 0.7 26 (93%) 133 (92%) 0.9 
 Weight (kg) 66.4 (8.6) 71.5 (14.5) 0.002 62.3 (8.8) 62.6 (12.5) 0.9 64.3 (9.8) 71.9 (16.7) 0.02 
 Sum of skinfolds (mm) 65.9 (16.0) 70.7 (20.5) 0.06 73.0 (17.9) 74.3 (19.5) 0.7 67.4 (14.5) 77.7 (21.5) 0.02 
 Triglycerides, median (IQR) (mmol/l) 1.06 (0.44) 1.13 (0.58) 0.02 1.26 (0.76) 1.32 (0.65) 0.6 1.04 (0.50) 1.27 (0.66) 0.03 
 Fasting glucose (mmol/l) 4.38 (0.42) 4.41 (0.38) 0.7 4.51 (0.35) 4.46 (0.42) 0.5 4.31 (0.32) 4.48 (0.49) 0.07 
 Severe vitamin D-deficiencya 0 (0) 6 (2) 0.2 27 (55) 63 (42) 0.1 8 (29) 55 (39) 0.3 
 Depressive sympt. (EPDS-score>10)b 10 (13) 20 (8) 0.1 5 (11) 28 (20) 0.1 2 (10) 20 (16) 0.5 
 No regular physical activityc 46 (55%) 185 (62%) 0.4 45 (92%) 132 (87%) 0.4 23 (82%) 127 (88%) 0.4 
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 1. -2. trimester weight gain (kg) 8.8 (4.0) 8.9 (4.7) 0.7 9.0 (4.5) 8.0 (4.6) 0.2 10.4 (4.4) 8.5 (5.2) 0.1 
 3.trimester weight gain (kg) 6.2 (3.6) 5.5 (3.8) 0.2 5.9 (4.0) 4.9 (3.9) 0.2 5.0 (4.3) 4.2 (5.2) 0.2 
Numbers are n (%) or mean (SD). Differences between women fulfilling, compared women not fulfilling the IG-21 criteria, were assessed using chi-square tests for 
categorical and t-tests for continuous variables. Significant differences (p-values <0.05) are written in bold. All variables, except depressive symptoms (28 gestational weeks 
and weight gain (28 gestational weeks (missing in 7% of women) and post-partum (missing in 24% of women)), were assessed at inclusion (at mean 15 gestational weeks). 
There are few (<1-2%) missing values for variables reported at inclusion, most participants have no missing variables. 
a25 OH vitamin D < 25 nmol/L.            
bMeasured at 28 gestational weeks, by the Edinburgh Postnatal Depression Scale.         
cModerately intensive activity for 30 min for ≥5 days/week, moderately intensive activity for 2.5 h/week over ≥3 days, vigorous-intensity activity for ≥20 min three times per 
week, or activity of both moderate and vigorous intensity. 




     
Table 4. Pregnancy complications and perinatal outcomes in women fulfilling, compared with not fulfilling the Intergrowth-21st criteria (IG-21 
criteria), stratified by ethnicity.    
    
Europe   South Asia   Middle East/N-Africa   
      





















criterai   
 
n=83 n=296   n=49 n=151   n=28 n=144   
Pregnancy complications                   
Gestational diabetes mellitusa 8 (10%) 33 (12%) 0.6 3 (6%) 25 (18%) 0.05 1 (4%) 23 (18%) 0.09 
Hypertensive disorder in pregnancyb 19 (6%) 7 (8%) 0.5 0 (0%) 11 (7%) 0.06 6 (4%) 2 (7%) 0.5 
Birth outcomes                   
Spontaneous initiation of labour 65 (80%) 216 (75%) 0.5 44 (90%) 109 (75%) 0.08 19 (76%) 105 (76%) 0.4 
Cesarean section 15 (18%) 55 (19%) 0.9 5 (10%) 27 (17%) 0.2 3 (11%) 21 (15%) 0.6 
Preterm birth (< 37gestational weeks) 3 (4%) 21 (7%) 0.3 4 (8%) 10 (7%) 0.7 2 (8%) 4 (3%) — 
Birth complicationsc                   
  Acute cesarean sectionc 12 (15%) 26 (10%) 0.2 4 (9%) 15 (11%) 0.7 3 (12%) 17 (13%) 0.9 
  Grade 3-4 perineal tearc 0 (0%) 10 (4%) — 4 (9%) 3 (2%) — 0 (0%) 4 (3%) — 
 Apgar score < 7 at 5 minc 0 (0%) 4 (2%) — 0 (0%) 1 (1%) — 0 (0%) 2 (2%) — 
  Composite three complicationsc, d 12 (15%) 38 (14%) 0.8 8 (17%) 22 (13%) 0.4 3 (12%) 22 (17%) 0.6 
Gender boyc 43 (55%) 137 (51%) 0.5 24 (55%) 68 (50%) 0.6 13 (52%) 52 (39%) 0.2 
Gestational age at birth (days)c 283 (10) 282 (9) 0.8 282 (8) 279 (10) 0.02 280 (9) 280 (10) 0.9 
Birth weight (g)c 3669 (478) 3610 (471) 0.3 3398 (399) 3247 (467) 0.06 3350 (435) 3480 (525) 0.2 
Head circumferencec 35.5 (1.4) 35.1 (1.3) 0.03 34.8 (1.2) 34.3 (1.3) 0.03 34.5 (1.1) 34.9 (1.5) 0.3 
Crown-heel-lengthc 50.6 (2.0) 50.3 (2.1) 0.3 49.8 (1.8) 49.5 (2.1) 0.5 49.6 (2.4) 49.7 (2.2) 0.8 
Low birth weight (<2500 g)c 1 (1%) 2 (1%) — 0 (0%) 6 (4%) — 0 (0%) 2 (2%) — 
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Numbers are n (%) or mean (SD). Differences between women fulfilling, compared women not fulfilling the IG-21 criteria, were assessed using chi-square tests for 
categorical and t-tests for continuous variables. Significant differences (p-values <0.05) are written in bold. Missing p-values is due to insufficient numbers of observations to 
perform chi-square test. 
aBy WHO 1999 criteria; Fasting plasma glucose ≥ 7 mmol/l or 2-hour plasma glucose ≥ 7.8 mmol/l).       
bSystolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg occurring from early pregnancy, or occurring after 20 weeks gestation, accompanied by 
new-onset proteinuria. Numbers are from hospital records.  
cNumbers are calculated from live born, singleton neonates, born at more than 37 gestational weeks, with birth data (as in the Intergrowth-21st study). In total there were 13 
abortions, 8 stillbirths/perinatal deaths, 11 twin-pairs and 8 were lost to follow-up with no birth data. 
dComposite score of three complication; acute cesarean section, grade 3-4 perineal rupture and Apgar score < 7 at 5 min. 
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